WASHINGTON (dpa-AFX) - Forest Laboratories (FRX) and Nabriva Therapeutics said they reached an agreement for the development of Nabriva's novel antibacterial agent, BC-3781.
Pursuant to the agreement, Forest will provide Nabriva with $25 million, and fund and conduct in collaboration with Nabriva, certain development activities related to BC-3781 over the next 12 months. During the 12-month period, Forest has the exclusive right to acquire Nabriva. Forest's decision to acquire Nabriva will be dependent upon certain contingencies. No further financial or other terms were disclosed.
Nabriva's lead systemic product, BC-3781, is being developed for the treatment of serious skin infections and bacterial pneumonia.
Copyright RTT News/dpa-AFX